Sarepta Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
260.00
-520.00
-689.00
-418.00
-553.00
-713.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-716.00
-481.00
-39.00
-98.00
554.00
-66.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-205.00
-500.00
-325.00
-443.00
107.00
-460.00
Cash Flow from Investing Activities
755.00
-165.00
-1,046.00
495.00
-121.00
286.00
Cash Flow from Financing Activities
124.00
125.00
232.00
561.00
682.00
646.00
Net Cash Inflow / Outflow
674.00
-541.00
-1,139.00
613.00
668.00
472.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Sarepta Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
260.774
1330.813
-1,070.00
-80.40%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-716.606
3036.793
-3,752.00
-123.60%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-205.787
2792.627
-2,997.00
-107.37%
Cash Flow from Investing Activities
755.561
-2696.649
3,451.00
128.02%
Cash Flow from Financing Activities
124.806
356.038
-232.00
-64.95%
Net Cash Inflow / Outflow
674.58
452.016
222.00
49.24%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 58.92% vs -53.99% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-205.79
-500.99
58.92%






